Table 2.
List of Anti-HNSCC Vaccines.
| Vaccine | Targeting Antigens | Clinical Trial ID | References |
|---|---|---|---|
| Peptide-based | |||
| GL-0810/0817 | MAGE-A3/HPV16 | NCT00257738 | Zandberg et al. 2015 |
| DPX-E7 vaccine | HPV16-E7 | NCT02865135 | Karkada et al. 2013 |
| HESPECTA | HPV E6 | NCT02821494 | Slingerland et al. 2016 |
| ISA101 | HPV16 E6/E7 | NCT02426892 | Kenter et al. 2008 |
| Anti-MUC1 | MUC1 | NCT02544880 | Weed et al. 2015 |
| TAA peptides | LY6K, CDCA1, and IMP3 | Phase II trial | Yoshitake et al. 2015 |
| p16(INK4a) vaccine | p16 | NCT01462838 | Reuschenbach et al. 2016 |
| Nucleic acid–based | |||
| INO-3112/INO-9012 | HPV16 /18 E6/7 | NCT02163057 | Bauml et al. 2016 |
| Allovectin-7 | Restore HLA-B7 / β2 | NCT00050388 | Gleich et al. 2001 |
| Pathogen-based | |||
| TG4001 | HPV16 E6/7 | NCT03260023 | N/A |
| ADXS11-001 | HPV16 E7 | NCT02002182 | Wallecha et al. 2012 |
| TRICOM | CEA and/or MUC1 | NCT00021424 | N/A |
| Cell-based | |||
| CSC-DC | ALDHhigh | Preclinical | Hu et al. 2016 |
| DC vaccine | p53 | NCT00404339 | Schuler et al. 2014 |
| MVX-ONCO-1 | Autologous tumor cells | NCT02999646 | Mach et al. 2016 |
ALDH, aldehyde dehydrogenase; β2, β2 microglobulin; CDCA1, cell division cycle associated 1; CEA, carcinoembryonic antigen; CSC-DC, cancer stem-like cell-based dendritic cell; DC, dendritic cell; HLA-B7, human leukocyte antigen B7; HNSCC, head and neck squamous cell carcinoma; HPV, human papilloma virus; IMP3, U3 small nucleolar ribonucleoprotein; LY6K, lymphocyte antigen 6 family member K; MAGE-A3, melanoma-specific antigen-A3; MUC1, mucin 1; N/A, not applicable; TAA, tumor-associated antigen.